Biotime Inc (BTX) 2.52 $BTX
BioTime, Inc. Subsidiary OncoCyte Corporation Expands Clinical Development of Bladder Cancer Diagnostic by Initiating a Large Multi-Site Clinical Trial
Business Wire - Thu Jul 31, 8:01AM CDT
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has expanded the clinical development of its urine-based bladder cancer diagnostic test by initiating a multi-site clinical trial. The trial, which will involve up to 1,200 patient samples obtained from at least four large urology clinics located throughout the United States, has received Institutional Review Board (IRB) approval at multiple sites and should begin enrolling patients within the next week. OncoCyte's initial clinical study of its bladder cancer diagnostic test began in January and involves pathology specimens being collected at a leading medical institution with an international reputation for excellence and discovery. The multi-site clinical trial, which has been initiated in part due to positive interim data from the ongoing study in pathology specimens, is designed to expand the potential use of the PanC-Dx(TM) bladder cancer test beyond pathology laboratories and into urologic practices at the point of cystoscopy. Cystoscopy along with urine cytopathology, are the standard methods utilized for bladder cancer screening and diagnosis. The multi-site clinical trial should be completed within 12 months.
Asterias Biotherapeutics Announces Live Investor Webcast
PR Newswire - Thu Jul 24, 2:30PM CDT
Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it will host a live webcast of a presentation to investors on Tuesday, July 29, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT. The presentation will include an overview of Asterias' business strategy and product development pipeline. To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. In accordance with applicable rules and regulations of the Securities and Exchange Commission, the webcast may be viewed only concurrently with the live presentation.
BioTime Announces Issuance of 14 Patents in the Fields of Regenerative Medicine, and Cancer Diagnosis and Therapy
Business Wire - Mon Jul 14, 8:01AM CDT
BioTime, Inc. (NYSE MKT:BTX) announced today the issuance of 14 new patents to BioTime and its subsidiary companies. The patents issued in Australia, Canada, China, Japan, and the United States, cover a wide range of core technologies foundational to BioTime's businesses. The new patents add to the largest known patent estate under one corporate umbrella in the field of pluripotent stem cell technology known as "regenerative medicine" with over 600 existing patents and patent applications owned or licensed to BioTime and its subsidiaries worldwide.
BioTime announces USD13.0m from equity financing of common stock & warrants
M2 - Wed Jun 18, 6:01AM CDT
Biotechnology company BioTime (NYSE MKT:BTX) said on Tuesday that its Asterias Biotherapeutics' subsidiary has raised USD12.5m through the sale of common shares and the issuance of warrants to investors.
BioTime Subsidiary Asterias Biotherapeutics Raises $13.0 Million in Equity Financing
Business Wire - Tue Jun 17, 8:01AM CDT
--Substantially strengthens Asterias' cash position
BioTime Subsidiary Asterias Biotherapeutics Announces Investment by CEO
Business Wire - Tue Jun 17, 7:30AM CDT
BioTime, Inc. (NYSE MKT: BTX) today announced that on June 12, 2014, Pedro Lichtinger, President and Chief Executive Officer of its subsidiary Asterias Biotherapeutics, Inc. ("Asterias"
purchased from Asterias 200,000 shares of Asterias Series B common stock at a price of $2.34 per share. The funds raised by this purchase will be used in part to finance Asterias' therapeutic product development programs, which are based on the potential of using human embryonic stem (hES) cells to create innovative new therapies for diseases and conditions for which effective treatments are not presently available.
BioTime Subsidiary Asterias Biotherapeutics Appoints Former Pfizer Senior Executive Pedro Lichtinger as President and Chief Executive Officer
Business Wire - Thu Jun 12, 8:01AM CDT
--Extensive Track Record of Successful Drug Development and Commercialization
BioTime to Present at the Jefferies 2014 Global Healthcare Conference
Business Wire - Mon Jun 02, 9:17AM CDT
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the Jefferies 2014 Global Healthcare Conference taking place June 2-5 in New York City. Dr. West will provide a corporate update in his presentation on Thursday, June 5, 2014, 9:00 AM EDT, at the Grand Hyatt New York.
BioTime's Subsidiary Asterias Biotherapeutics, Inc. Announces a $14.3 Million Strategic Partnership Award from the California Institute for Regenerative Medicine
Business Wire - Fri May 30, 7:30AM CDT
--Funding Provides for the Expansion of AST-OPC1 Clinical Trial Originally Initiated by Geron Corporation into Target Population for Pivotal Studies
BioTime passes BSI ISO 13485 certification for HyStem hydrogels
M2 - Thu May 29, 3:06AM CDT
Biotechnology company BioTime (NYSE MKT:BTX) disclosed on Wednesday the receipt of ISO 13485:2003 certification for design, development, manufacture and distribution of its HyStem hydrogels for cell delivery applications from BSI (British Standards Institution).
BioTime's Subsidiary Asterias Biotherapeutics, Inc. Settles Patent Interference Proceedings
Business Wire - Wed May 28, 8:02AM CDT
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Asterias Biotherapeutics, Inc. ("Asterias" , announced that Asterias has entered into a settlement agreement with ViaCyte, Inc. ("ViaCyte" concerning certain litigation in the United States District Court for the Northern District of California (Civil Action No. C12-04813) seeking the reversal of two adverse determinations by the United States Patent & Trademark Office with respect to two patent applications in U.S. Patent Interference 105,734, involving U.S. patent 7,510,876 (ViaCyte) and U.S. patent application 11/960,477 (Geron), and U.S. Patent Interference 105,827 involving U.S. patent 7,510,876 (ViaCyte) and U.S. patent application 12/543,875 (Geron), along with four Opposition Proceedings pending before the Australian Patent Office pertaining to priority rights and the validity of each party's patents relating to endodermal precursor cells. Under the terms of the settlement agreement, the parties granted to each other a royalty free, fully paid license to each other's technology relating to endoderm lineage cells including definitive endoderm and gut endoderm cells, only to the extent necessary to allow the licensee to make, use, sell, offer for sale, or import endodermal lineage cells.
BioTime Receives ISO 13485 Certification for Medical Devices
Business Wire - Wed May 28, 7:45AM CDT
BioTime, Inc. (NYSE MKT: BTX) today announced that it has received ISO 13485:2003 certification from BSI (British Standards Institution) for design, development, manufacture, and distribution of BioTime HyStem(R) hydrogels for cell delivery applications.
BioTime's Subsidiary OncoCyte Corporation and Cornell University Enter License Agreement to Accelerate Lung Cancer Diagnostic Product Development
Business Wire - Tue May 27, 8:02AM CDT
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has entered into a License Agreement with Cornell University through which Weill Cornell Medical College will provide blood samples derived from healthy people and lung cancer patients for comparative analysis using the Company's proprietary PanC-Dx(TM) diagnostic tests. OncoCyte scientists will determine levels of tumor-associated gene expression in these samples, including assessing levels of its proprietary PanC-Dx(TM) cancer markers. The results of these analyses, along with the results of the nearly complete clinical study currently being conducted by OncoCyte's collaborators at The Wistar Institute, will be combined to produce a data set from over 700 patients. This data will be used by OncoCyte to assess the performance of potential cancer markers for the purpose of developing a multi-marker test for the detection of lung cancer. As part of the License, OncoCyte retains all rights to develop and market its proprietary lung cancer diagnostic products.
Asterias Biotherapeutics, Inc. Launches New Website: Asteriasbiotherapeutics.com
Business Wire - Wed May 21, 8:15AM CDT
Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX) that is developing clinical-stage stem cell therapeutic assets acquired from Geron Corporation, today announced the launch of its new website, www.asteriasbiotherapeutics.com. The website provides information about Asterias, including its core technologies, areas of product development focus, intellectual property portfolio, key publications, SEC filings, and management team.
BioTime To Present at Regen Med Investor Day March 26 in New York
Business Wire - Tue Mar 25, 8:03AM CDT
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City.
BioTime Announces Fourth Quarter and Fiscal Year End 2013 Financial Results and Recent Corporate Accomplishments
Business Wire - Mon Mar 17, 5:52PM CDT
BioTime, Inc. (NYSE MKT: BTX), today reported financial results for the fourth quarter and year ended December 31, 2013 and highlighted its fourth quarter and recent corporate accomplishments.
5 Stocks With Big Insider Buying
at The Street - Wed Mar 05, 11:30AM CST
Insiders at these companies have been scooping up shares of their own stock lately.
BioTime Raises $3.5 Million Through Preferred Stock Offering
Business Wire - Wed Mar 05, 8:01AM CST
BioTime, Inc. (NYSE MKT: BTX) today announced it has sold 70,000 shares of a newly authorized Series A Convertible Preferred Stock for $3.5 million. The Series A Preferred Stock carries a cumulative annual 3% preferred dividend or $1.50 per share, in preference to BioTime common shares. Each share of Series A Preferred Stock is convertible, at the election of the holder, into BioTime common shares at a conversion price of $4.00 per share, a current conversion ratio of 12.5 common shares for each share of Series A Preferred Stock.
BioTime Provides Financing and Product Development Update
Business Wire - Mon Mar 03, 8:00AM CST
--Company is Awarded New NIH SBIR Grant
BioTime CEO Dr. Michael West to Present at 9th Annual Stem Cell Summit
Business Wire - Tue Feb 18, 7:45AM CST
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the 9th Annual Stem Cell Summit in New York. Dr. West will speak in the session "Disrupting the Pharma Model with Allogeneic Stem Cell Therapies" on February 18, 2014, starting at 9:05 a.m. EST.
BioTime, Inc. Subsidiary OncoCyte Corporation Expands Clinical Development of Bladder Cancer Diagnostic by Initiating a Large Multi-Site Clinical Trial
Business Wire - Thu Jul 31, 8:01AM CDT
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has expanded the clinical development of its urine-based bladder cancer diagnostic test by initiating a multi-site clinical trial. The trial, which will involve up to 1,200 patient samples obtained from at least four large urology clinics located throughout the United States, has received Institutional Review Board (IRB) approval at multiple sites and should begin enrolling patients within the next week. OncoCyte's initial clinical study of its bladder cancer diagnostic test began in January and involves pathology specimens being collected at a leading medical institution with an international reputation for excellence and discovery. The multi-site clinical trial, which has been initiated in part due to positive interim data from the ongoing study in pathology specimens, is designed to expand the potential use of the PanC-Dx(TM) bladder cancer test beyond pathology laboratories and into urologic practices at the point of cystoscopy. Cystoscopy along with urine cytopathology, are the standard methods utilized for bladder cancer screening and diagnosis. The multi-site clinical trial should be completed within 12 months.
Asterias Biotherapeutics Announces Live Investor Webcast
PR Newswire - Thu Jul 24, 2:30PM CDT
Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it will host a live webcast of a presentation to investors on Tuesday, July 29, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT. The presentation will include an overview of Asterias' business strategy and product development pipeline. To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. In accordance with applicable rules and regulations of the Securities and Exchange Commission, the webcast may be viewed only concurrently with the live presentation.
BioTime Announces Issuance of 14 Patents in the Fields of Regenerative Medicine, and Cancer Diagnosis and Therapy
Business Wire - Mon Jul 14, 8:01AM CDT
BioTime, Inc. (NYSE MKT:BTX) announced today the issuance of 14 new patents to BioTime and its subsidiary companies. The patents issued in Australia, Canada, China, Japan, and the United States, cover a wide range of core technologies foundational to BioTime's businesses. The new patents add to the largest known patent estate under one corporate umbrella in the field of pluripotent stem cell technology known as "regenerative medicine" with over 600 existing patents and patent applications owned or licensed to BioTime and its subsidiaries worldwide.
BioTime announces USD13.0m from equity financing of common stock & warrants
M2 - Wed Jun 18, 6:01AM CDT
Biotechnology company BioTime (NYSE MKT:BTX) said on Tuesday that its Asterias Biotherapeutics' subsidiary has raised USD12.5m through the sale of common shares and the issuance of warrants to investors.
BioTime Subsidiary Asterias Biotherapeutics Raises $13.0 Million in Equity Financing
Business Wire - Tue Jun 17, 8:01AM CDT
--Substantially strengthens Asterias' cash position
BioTime Subsidiary Asterias Biotherapeutics Announces Investment by CEO
Business Wire - Tue Jun 17, 7:30AM CDT
BioTime, Inc. (NYSE MKT: BTX) today announced that on June 12, 2014, Pedro Lichtinger, President and Chief Executive Officer of its subsidiary Asterias Biotherapeutics, Inc. ("Asterias"
purchased from Asterias 200,000 shares of Asterias Series B common stock at a price of $2.34 per share. The funds raised by this purchase will be used in part to finance Asterias' therapeutic product development programs, which are based on the potential of using human embryonic stem (hES) cells to create innovative new therapies for diseases and conditions for which effective treatments are not presently available. BioTime Subsidiary Asterias Biotherapeutics Appoints Former Pfizer Senior Executive Pedro Lichtinger as President and Chief Executive Officer
Business Wire - Thu Jun 12, 8:01AM CDT
--Extensive Track Record of Successful Drug Development and Commercialization
BioTime to Present at the Jefferies 2014 Global Healthcare Conference
Business Wire - Mon Jun 02, 9:17AM CDT
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the Jefferies 2014 Global Healthcare Conference taking place June 2-5 in New York City. Dr. West will provide a corporate update in his presentation on Thursday, June 5, 2014, 9:00 AM EDT, at the Grand Hyatt New York.
BioTime's Subsidiary Asterias Biotherapeutics, Inc. Announces a $14.3 Million Strategic Partnership Award from the California Institute for Regenerative Medicine
Business Wire - Fri May 30, 7:30AM CDT
--Funding Provides for the Expansion of AST-OPC1 Clinical Trial Originally Initiated by Geron Corporation into Target Population for Pivotal Studies
BioTime passes BSI ISO 13485 certification for HyStem hydrogels
M2 - Thu May 29, 3:06AM CDT
Biotechnology company BioTime (NYSE MKT:BTX) disclosed on Wednesday the receipt of ISO 13485:2003 certification for design, development, manufacture and distribution of its HyStem hydrogels for cell delivery applications from BSI (British Standards Institution).
BioTime's Subsidiary Asterias Biotherapeutics, Inc. Settles Patent Interference Proceedings
Business Wire - Wed May 28, 8:02AM CDT
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Asterias Biotherapeutics, Inc. ("Asterias"
, announced that Asterias has entered into a settlement agreement with ViaCyte, Inc. ("ViaCyte" concerning certain litigation in the United States District Court for the Northern District of California (Civil Action No. C12-04813) seeking the reversal of two adverse determinations by the United States Patent & Trademark Office with respect to two patent applications in U.S. Patent Interference 105,734, involving U.S. patent 7,510,876 (ViaCyte) and U.S. patent application 11/960,477 (Geron), and U.S. Patent Interference 105,827 involving U.S. patent 7,510,876 (ViaCyte) and U.S. patent application 12/543,875 (Geron), along with four Opposition Proceedings pending before the Australian Patent Office pertaining to priority rights and the validity of each party's patents relating to endodermal precursor cells. Under the terms of the settlement agreement, the parties granted to each other a royalty free, fully paid license to each other's technology relating to endoderm lineage cells including definitive endoderm and gut endoderm cells, only to the extent necessary to allow the licensee to make, use, sell, offer for sale, or import endodermal lineage cells. BioTime Receives ISO 13485 Certification for Medical Devices
Business Wire - Wed May 28, 7:45AM CDT
BioTime, Inc. (NYSE MKT: BTX) today announced that it has received ISO 13485:2003 certification from BSI (British Standards Institution) for design, development, manufacture, and distribution of BioTime HyStem(R) hydrogels for cell delivery applications.
BioTime's Subsidiary OncoCyte Corporation and Cornell University Enter License Agreement to Accelerate Lung Cancer Diagnostic Product Development
Business Wire - Tue May 27, 8:02AM CDT
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has entered into a License Agreement with Cornell University through which Weill Cornell Medical College will provide blood samples derived from healthy people and lung cancer patients for comparative analysis using the Company's proprietary PanC-Dx(TM) diagnostic tests. OncoCyte scientists will determine levels of tumor-associated gene expression in these samples, including assessing levels of its proprietary PanC-Dx(TM) cancer markers. The results of these analyses, along with the results of the nearly complete clinical study currently being conducted by OncoCyte's collaborators at The Wistar Institute, will be combined to produce a data set from over 700 patients. This data will be used by OncoCyte to assess the performance of potential cancer markers for the purpose of developing a multi-marker test for the detection of lung cancer. As part of the License, OncoCyte retains all rights to develop and market its proprietary lung cancer diagnostic products.
Asterias Biotherapeutics, Inc. Launches New Website: Asteriasbiotherapeutics.com
Business Wire - Wed May 21, 8:15AM CDT
Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX) that is developing clinical-stage stem cell therapeutic assets acquired from Geron Corporation, today announced the launch of its new website, www.asteriasbiotherapeutics.com. The website provides information about Asterias, including its core technologies, areas of product development focus, intellectual property portfolio, key publications, SEC filings, and management team.
BioTime To Present at Regen Med Investor Day March 26 in New York
Business Wire - Tue Mar 25, 8:03AM CDT
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City.
BioTime Announces Fourth Quarter and Fiscal Year End 2013 Financial Results and Recent Corporate Accomplishments
Business Wire - Mon Mar 17, 5:52PM CDT
BioTime, Inc. (NYSE MKT: BTX), today reported financial results for the fourth quarter and year ended December 31, 2013 and highlighted its fourth quarter and recent corporate accomplishments.
5 Stocks With Big Insider Buying
at The Street - Wed Mar 05, 11:30AM CST
Insiders at these companies have been scooping up shares of their own stock lately.
BioTime Raises $3.5 Million Through Preferred Stock Offering
Business Wire - Wed Mar 05, 8:01AM CST
BioTime, Inc. (NYSE MKT: BTX) today announced it has sold 70,000 shares of a newly authorized Series A Convertible Preferred Stock for $3.5 million. The Series A Preferred Stock carries a cumulative annual 3% preferred dividend or $1.50 per share, in preference to BioTime common shares. Each share of Series A Preferred Stock is convertible, at the election of the holder, into BioTime common shares at a conversion price of $4.00 per share, a current conversion ratio of 12.5 common shares for each share of Series A Preferred Stock.
BioTime Provides Financing and Product Development Update
Business Wire - Mon Mar 03, 8:00AM CST
--Company is Awarded New NIH SBIR Grant
BioTime CEO Dr. Michael West to Present at 9th Annual Stem Cell Summit
Business Wire - Tue Feb 18, 7:45AM CST
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the 9th Annual Stem Cell Summit in New York. Dr. West will speak in the session "Disrupting the Pharma Model with Allogeneic Stem Cell Therapies" on February 18, 2014, starting at 9:05 a.m. EST.
